Due to the major challenges in both diagnostic and therapeutic modalities in pulmonary fibrosis (PF), it is important to continue identifying novel and viable drug targets to combat pathogenesis associated with the disease. We propose to use a combination of traditional molecular biology techniques and high-throughput lipidomics and proteomics approaches to identify novel protein and lipid biomarkers, and investigate their contribution to PF. The long-term goal is to develop an effective therapeutic strategy against PF, and this study is directly relevant to the mission of National Heart, Lung and Blood Institute. The overall objective of the proposed study is to identify novel biomarkers and study the interplay between lipogenic and angiogenic mediators that may be targeted for treatment of PF. Recent evidence suggests an important role for lipid mediators in PF, but little is known about the deregulation of overall lipid composition in disease progression. Preliminary data suggests a critical role for fatty acid synthase (FASN), an important lipogenic enzyme associated with lung injury, in bleomycin (BLM)-induced PF.
Aim 1 is designed to investigate the role of FASN in the pathogenesis of PF and identify key FASN-associated lipid and protein partners. Preliminary proteomic analysis of BLM-treated mouse lung tissue identified Phosphatidylinositol-3-kinase/Protein Kinase B (PI3K/Akt) and Wnt (Wingless Integration-1)/beta(?)-catenin signaling pathways as the two most important fibrotic pathways involved. PI3K/Akt and Wnt/?-catenin pathways have been shown to potentiate fibrotic response, and we have reported on the critical role of vascular endothelial growth factor (VEGF), a direct target of PI3K/Akt pathway, in regulating fibrosis. FASN is known to regulate VEGF in other lung diseases such as asthma, and activate Wnt/?-catenin signaling in breast and prostate cancers. We hypothesize that FASN exerts its effects in PF by regulating PI3K/Akt>VEGF and Wnt/?-catenin pathways.
Aim 2 is designed to investigate the mechanistic effect of Wnt/?-catenin and PI3K/Akt>VEGF signaling on regulation of FASN in BLM-induced PF. Our ongoing in vivo studies demonstrates that FASN inhibitor Orlistat significantly inhibited BLM-induced PF. Furthermore, a strong interplay has emerged between FASN, VEGF and Wnt/?-catenin signaling in PF.
Aim 3 is designed to evaluate whether anti-FASN agents such as Orlistat mediate lung fibrosis by regulating PI3K/Akt>VEGF and Wnt/?-catenin signaling pathways, and investigate the potential development of a co-therapy regimen involving Orlistat and inhibitors of the PI3K/Akt>VEGF and Wnt/?-catenin pathways. Investigation of this crosstalk and identification of related key biomarkers will be important for the increased understanding of the molecular mechanisms involved in the pathogenesis of PF and will facilitate development of potential therapeutic and preventive strategies for this fatal disease.

Public Health Relevance

PROJECTIVE NARRATIVE The interplay of lipogenic and angiogenic mediators represents an unexplored and innovative mechanism in pulmonary fibrosis with substantial prognostic and therapeutic potential. In this study, high-throughput ?omics?- based approach will be used to identify novel lipid mediators in the pathogenesis of pulmonary fibrosis and their potential cross-talk with angiogenic mediators will be investigated. This study will provide insight into hitherto unexplored mechanistic aspects related to lipogenesis and angiogenesis, and will help identify novel protein and lipid biomarkers that may be targeted to achieve viable therapeutic outcomes against pulmonary fibrosis. Defining the impact of these novel biomarkers and pathways in the pathogenesis of pulmonary fibrosis may lead to a paradigm shift in the current understanding of the disease, and pave way for tackling fibrosis using novel approaches.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Enhancement Award (SC1)
Project #
9SC1GM121287-06A1
Application #
9417549
Study Section
Special Emphasis Panel (ZGM1)
Program Officer
Zlotnik, Hinda
Project Start
2011-09-01
Project End
2022-05-31
Budget Start
2018-06-26
Budget End
2019-05-31
Support Year
6
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Hampton University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
003135068
City
Hampton
State
VA
Country
United States
Zip Code
23668